Among patients with microsatellite-stable cancer, this analysis found a statistically significant difference in incidence of KRAS variants, with 52.4% among LO and 45.6% among YO tumors.7 In 2019, Willauer et al4 characterized YO cancers into unique molecular subtypes by analyzing 36 000 patient samples from 4 combined cohorts. The gene discussed is KRAS; the disease is cancer.